These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12620461)

  • 1. Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist.
    Schröder AK; Schöpper B; Al-Hasani S; Löning M; Diedrich K; Ludwig M
    Fertil Steril; 2003 Mar; 79(3):648-50. PubMed ID: 12620461
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH antagonists in poor responders.
    Kolibianakis E; Albano C; Zikopoulos K; Kahn JA; Van Steirteghem A; Devroey P
    Acta Obstet Gynecol Scand; 2004 Dec; 83(12):1216-7. PubMed ID: 15548159
    [No Abstract]   [Full Text] [Related]  

  • 4. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
    Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled ovarian stimulation using a long gonadotropin-releasing hormone antagonist protocol: a proof of concept and feasibility study.
    Weissman A; Ravhon A; Steinfeld Z; Nahum H; Golan A; Levran D
    Gynecol Obstet Invest; 2013; 76(2):113-8. PubMed ID: 23920048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of mild and microdose GnRH agonist flare protocols on IVF outcome in poor responders.
    Karimzadeh MA; Mashayekhy M; Mohammadian F; Moghaddam FM
    Arch Gynecol Obstet; 2011 May; 283(5):1159-64. PubMed ID: 21221982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of modified agonist, mild-stimulation and antagonist protocols for in vitro fertilization in patients with diminished ovarian reserve.
    Yu R; Jin H; Huang X; Lin J; Wang P
    J Int Med Res; 2018 Jun; 46(6):2327-2337. PubMed ID: 29695208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis.
    Bosch E; Labarta E; Crespo J; Simón C; Remohí J; Pellicer A
    Fertil Steril; 2011 Mar; 95(3):1031-6. PubMed ID: 21067717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462).
    Itskovitz-Eldor J; Kol S; Mannaerts B; Coelingh Bennink H
    Hum Reprod; 1998 Feb; 13(2):294-5. PubMed ID: 9557825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal stimulation using gonadotropin-releasing hormone (GnRH) antagonist and recombinant human follicle-stimulating hormone versus GnRH antagonist multiple-dose protocol in low responders undergoing in vitro fertilization/intracytoplasmic sperm injection.
    Kim CH; Kim SR; Cheon YP; Kim SH; Chae HD; Kang BM
    Fertil Steril; 2009 Dec; 92(6):2082-4. PubMed ID: 19589522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report: successful pregnancy after controlled ovarian hyperstimulation by using short-acting gonadotropin releasing hormone agonist only.
    Gong F; Cai S; Zhang S; Lu C; Lin G; Lu G
    J Assist Reprod Genet; 2012 Apr; 29(4):329-30. PubMed ID: 22318292
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of gonadotropin releasing hormone agonist long protocol and gonadotropin releasing hormone antagonist protocol in infertile women].
    Ren Y; Yang S; Yang R; Li R; Chen XN; Wang HY; Ma CH; Liu P; Qiao J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):877-81. PubMed ID: 24343066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome.
    Şükür YE; Özmen B; Özdemir ED; Seval MM; Kalafat E; Sönmezer M; Berker B; Aytaç R; Atabekoğlu CS
    Reprod Biomed Online; 2017 Jan; 34(1):5-10. PubMed ID: 27771155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of gonadotropin-releasing hormone antagonist in a flexible protocol: a pilot study.
    Mansour RT; Aboulghar MA; Serour GI; Al-Inany HG; Amin YM; Abou-Setta AM
    Am J Obstet Gynecol; 2003 Aug; 189(2):444-6. PubMed ID: 14520215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist.
    Giampietro F; Sancilio S; Tiboni GM; Rana RA; Di Pietro R
    Fertil Steril; 2006 Feb; 85(2):412-9. PubMed ID: 16595220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.